Current status of the treatment of hepatocellular carcinoma with pulmonary metastasis

doi:10.3877/cma.j.issn.1674-0793.2022.02.012

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death in China, and extrahepatic metastasis is an important reason for its poor prognosis. With the continuous progress of imaging technology, the detection rate of HCC with extrahepatic metastasis is increasing year by year, among which the lung is the most common extrahepatic metastatic organ. The situation of HCC patients with lung metastasis is complex, which is very difficult to deal with and the treatment mode is still inconclusive. All kinds of guidelines only recommend systematic treatment, but with little effect. In this paper, various treatments for lung metastasis of HCC are summarized in order to provide the best individualized comprehensive treatment strategy for patients, so as to improve their survival benefits.

Key words: Hepatocellular carcinoma, Pulmonary metastasis, Treatment, Review

Tonghui Lu, Feng Xu. Current status of the treatment of hepatocellular carcinoma with pulmonary metastasis[J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(02): 141-145.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2022.02.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2022/V16/I02/141

References 39

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2(1): 1-9.
[2]	Wu W, He X, Andayani D, et al. Pattern of distant extrahepatic metastases in primary liver cancer: A SEER based study[J]. J Cancer, 2017, 8(12): 2312-2318.
[3]	Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: A population-based study[J]. Cancer Manag Res, 2019, 11: 2759-2768.
[4]	Hu Z, Li W, Huang P, et al. Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection[J]. Int J Surg, 2017, 48: 23-31.
[5]	Lee HP, Yun JK, Jung HS, et al. Surgical outcomes of pulmonary metastasectomy in hepatocellular carcinoma patients according to approach method: thoracoscopic versus open approach[J]. World J Surg Oncol, 2021, 19(1): 33.
[6]	Mizuguchi S, Nishiyama N, Izumi N, et al. Clinical significance of multiple pulmonary metastasectomy for hepatocellular carcinoma[J]. World J Surg, 2016, 40(2): 380-387.
[7]	Kuo TM, Chang KM, Cheng TI, et al. Clinical factors predicting better survival outcome for pulmonary metastasectomy of hepatocellular carcinoma[J]. Liver Cancer, 2017, 6(4): 297-306.
[8]	叶欣，范卫君，王徽, 等. 热消融治疗原发性和转移性肺部肿瘤专家共识（2017年版）[J]. 中国肺癌杂志, 2017, 20(7): 433-445.
[9]	葛夕洪，刘祥，蔡金贞, 等. 肝癌肝移植术后肺寡转移瘤的微波消融治疗效果分析[J/CD]. 实用器官移植电子杂志, 2020, 8(5): 349-352.
[10]	Yuan Z, Liu B, Hu C, et al. Clinical outcomes of percutaneous thermal ablation for pulmonary metastases from hepatocellular carcinoma: A retrospective study[J]. Int J Hyperthermia, 2020, 37(1): 651-659.
[11]	Zuo T, Lin W, Liu F, et al. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum[J]. BMC Cancer, 2021, 21(1): 505.
[12]	Hori A, Ohira R, Nakamura T, et al. Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma[J]. Br J Radiol, 2020, 93(1110): 20190407.
[13]	李科，孔轶. 进口碘化油TACE联合洛铂治疗晚期肝癌肺转移的临床疗效观察[J]. 实用癌症杂志, 2018, 33(2): 244-246.
[14]	Wang Z, Kong QT, Li J, et al. Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases[J]. J Thorac Dis, 2015, 7(3): 407-412.
[15]	Zhang F, Wang J, Guo J, et al. Chinese Expert Consensus Workshop Report: Guideline for permanent iodine-125 seed implantation of primary and metastatic lung tumors[J]. Thorac Cancer, 2019, 10(2): 388-394.
[16]	Zhang L, Chen LH, Wang J, et al. CT-guided radioactive ¹²⁵I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol, 2014, 69(6): 624-629.
[17]	Soliman H, Ringash J, Jiang H, et al. Phase Ⅱ trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases[J]. J Clin Oncol, 2013, 31(31): 3980-3986.
[18]	Pelizzaro F, Sammarco A, Dadduzio V, et al. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience[J]. Dig Liver Dis, 2019, 51(12): 1713-1719.
[19]	Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
[20]	Hasegawa H, Kawakubo E, Kitagawa D, et al. Combined modality therapy for giant hepatocellular carcinoma and multiple lung metastases-a case study[J]. Gan To Kagaku Ryoho, 2020, 47(13): 2251-2253.
[21]	Shi J, Sun J, Liu C, et al. All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial[J]. Trials, 2019, 20(1): 245.
[22]	Mao X, Tey SK, Yeung C, et al. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1[J]. Adv Sci(Weinh), 2020, 7(21): 2002157.
[23]	Yoshida M, Yamashita T, Okada H, et al. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90[J]. Sci Rep, 2017, 7(1): 11292.
[24]	冯跃，郑家平，邵国良. 索拉非尼治疗肝细胞癌肺转移39例预后分析[J]. 肿瘤学杂志, 2018, 24(10): 987-991.
[25]	Yang T, Lu JH, Lin C, et al. Concomitant lung metastasis in patients with advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2012, 18(20): 2533-2539.
[26]	Chen J, Lu S, Zhang Y, et al. Sorafenib monotherapy versus sorafenib combined with regional therapies for hepatocellular carcinoma patients with pulmonary oligometastases: A propensity score-matched analysis[J]. J Cancer, 2018, 9(10): 1745-1753.
[27]	Li ZJ, Dai HQ, Huang XW, et al. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma[J]. Acta Pharmacol Sin, 2021, 42(2): 301-310.
[28]	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[29]	Lee MJ, Chang SW, Kim JH, et al. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: A multicenter retrospective study in Korea[J]. Invest New Drugs, 2021, 39(1): 260-268.
[30]	Du X, Chen D, Lin Z, et al. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: A retrospective, multicenter study[J]. J BUON, 2019, 24(5): 1956-1963.
[31]	Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296.
[32]	El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[33]	Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase Ⅰ/Ⅱ study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis[J]. J Hepatol, 2021, 75(3): 600-609.
[34]	Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90.
[35]	Kim CG, Kim C, Yoon SE, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2021, 74(2): 350-359.
[36]	Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): e204564.
[37]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[38]	Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
[39]	Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.

Please choose a citation manager

Content to export